Reuters logo
BRIEF-Achillion Pharmaceuticals says Joel Barrish plans to leave co
2017年7月10日 / 晚上8点18分 / 4 个月前

BRIEF-Achillion Pharmaceuticals says Joel Barrish plans to leave co

July 10 (Reuters) - Achillion Pharmaceuticals Inc

* Achillion Pharmaceuticals Inc - ‍announced that Joel Barrish, executive vice president and chief scientific officer, plans to leave company

* Achillion Pharmaceuticals Inc - Achillion continues to dose PNH patients in a phase 2 study of its first complement factor D inhibitor, ACH-4471​

* Achillion Pharmaceuticals Inc - ‍ACH-4471 is also poised to begin a phase 2 clinical study in C3G​ Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below